| Title : Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models - Thomas_2009_J.Pharmacol.Exp.Ther_328_556 |
| Author(s) : Thomas L , Tadayyon M , Mark M |
| Ref : Journal of Pharmacology & Experimental Therapeutics , 328 :556 , 2009 |
| Abstract : Thomas_2009_J.Pharmacol.Exp.Ther_328_556 |
| ESTHER : Thomas_2009_J.Pharmacol.Exp.Ther_328_556 |
| PubMedSearch : Thomas_2009_J.Pharmacol.Exp.Ther_328_556 |
| PubMedID: 18971371 |
Thomas L, Tadayyon M, Mark M (2009)
Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models
Journal of Pharmacology & Experimental Therapeutics
328 :556
Thomas L, Tadayyon M, Mark M (2009)
Journal of Pharmacology & Experimental Therapeutics
328 :556